Loading
A phase 1/2 trial of Epcoritamab, Rituximab, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) is a phase 1/2 interventional study registered as NCT04542824 by Genmab, with 78 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2027-09. Interventions recorded: Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Gemcitabine and oxaliplatin, Epcoritamab (maintenance). Conditions listed: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).